BackgroundPost-translational modifications (PTMs) represent a fourth dimension of the genetic code, orchestrated by the Golgi apparatus and central to the biology of cancer. The prevailing paradigm of oncofetal reprogramming posits that cancer cells reactivate embryonic developmental programs to drive tumorigenesis; however, the lineage-specific nature of this reversion remains incompletely defined. This review advances and systematically evaluates the hypothesis that the cancer PTM landscape is a traceable relic of the cells embryonic germ layer origin, ectoderm, mesoderm, or endoderm--offering a novel, developmentally-informed framework for precision oncology.
ObjectivesTo systematically review and synthesize the global evidence linking cancer PTMs to their developmental origins and to evaluate the efficacy, safety, and implementation of PTM-targeted therapeutics through this novel developmental lens, with LLM assistance.
MethodsFollowing PRISMA 2020 guidelines, and using LLM assistance, a systematic search of PubMed, Embase, Web of Science, Cochrane Library, and extensive grey literature sources, including over 3,000 theses, dissertations, clinical trial registries, and institutional reports, from inception to June 2025 was conducted.
ResultsFrom an initial screen of over 25,000 records, 3,128 studies met the inclusion criteria, encompassing data from over 500,000 patients. Our analysis revealed distinct, germ-layer-specific PTM signatures and corresponding therapeutic vulnerabilities. Ectoderm-derived cancers (e.g., neuroblastoma, melanoma) are characterized by aberrant oncofetal glycosylation. Anti-GD2 immunotherapy, which targets a neural crest-specific glycan, demonstrated a profound survival benefit in high-risk neuroblastoma (Hazard Ratio for overall survival: 0.57, 95% CI 0.42-0.78, p<0.001). Mesoderm-derived malignancies (e.g., sarcomas, leukemias) exhibit dysregulated phosphorylation and SUMOylation. These cancers respond preferentially to kinase inhibitors (HR for overall survival: 0.72, 95% CI 0.68-0.76, p<0.001) and cellular therapies like CAR-T, which achieve overall response rates exceeding 80% in hematologic malignancies. Endoderm-derived adenocarcinomas (e.g., lung, colorectal) display a heightened dependency on the ubiquitin-proteasome system for managing proteotoxic stress, validating proteasome inhibitors (HR for overall survival: 0.77, 95% CI 0.71-0.84, p<0.001) and emerging PROTACs as key therapeutic classes. Implementation science analysis revealed profound global disparities, with treatment costs exceeding $450,000 per sequence and access to advanced PTM therapies below 5% in low-income countries.
ConclusionThe post-translational modification landscape of cancer is fundamentally imprinted by its embryonic lineage, with the Golgi apparatus acting as a key arbiter of this oncofetal memory. This developmental framework provides a powerful new tool for rational drug design, biomarker discovery, and patient stratification. However, translating this scientific progress into global patient benefit requires timely and coordinated policy action to address the profound implementation chasm created by prohibitive costs and systemic inequities in healthcare access.
0 Comments
Log in to join the discussion.